Abeona Therapeutics (ABEO) Competitors

$5.49 -0.11 (-1.96%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$5.53 +0.04 (+0.69%)

As of 05/15/2026 07:56 PM Eastern

ABEO vs. GHRS, CRVS, OLMA, MAZE, and CMPS

Should you buy Abeona Therapeutics stock or one of its competitors? MarketBeat compares Abeona Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abeona Therapeutics include GH Research (GHRS), Corvus Pharmaceuticals (CRVS), Olema Pharmaceuticals (OLMA), Maze Therapeutics (MAZE), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Abeona Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

GH Research has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

GH Research presently has a consensus price target of $41.00, indicating a potential upside of 91.68%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 246.08%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

GH Research's return on equity of -19.36% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Abeona Therapeutics	N/A	-53.98%	-38.52%

In the previous week, Abeona Therapeutics had 9 more articles in the media than GH Research. MarketBeat recorded 16 mentions for Abeona Therapeutics and 7 mentions for GH Research. Abeona Therapeutics' average media sentiment score of 0.42 beat GH Research's score of -0.07 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

56.9% of GH Research shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A
Abeona Therapeutics	$5.82M	53.76	$71.18M	$1.03	5.33

Summary

Abeona Therapeutics beats GH Research on 9 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Corvus Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Abeona Therapeutics	$5.82M	53.76	$71.18M	$1.03	5.33

In the previous week, Abeona Therapeutics had 9 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 16 mentions for Abeona Therapeutics and 7 mentions for Corvus Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.42 beat Corvus Pharmaceuticals' score of 0.07 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 170.78%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 246.08%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Corvus Pharmaceuticals' return on equity of -38.92% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Abeona Therapeutics beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Olema Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Abeona Therapeutics	$5.82M	53.76	$71.18M	$1.03	5.33

In the previous week, Abeona Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 16 mentions for Abeona Therapeutics and 14 mentions for Olema Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.42 beat Olema Pharmaceuticals' score of -0.24 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 224.50%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 246.08%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Olema Pharmaceuticals' return on equity of -46.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Abeona Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Maze Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

80.6% of Abeona Therapeutics shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abeona Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.76	$71.18M	$1.03	5.33
Maze Therapeutics	$167.50M	8.45	-$131.12M	-$2.53	N/A

Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 246.08%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 158.22%. Given Abeona Therapeutics' higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Abeona Therapeutics had 10 more articles in the media than Maze Therapeutics. MarketBeat recorded 16 mentions for Abeona Therapeutics and 6 mentions for Maze Therapeutics. Abeona Therapeutics' average media sentiment score of 0.42 beat Maze Therapeutics' score of -0.08 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Maze Therapeutics' return on equity of -36.62% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Maze Therapeutics	N/A	-36.62%	-31.78%

Summary

Abeona Therapeutics beats Maze Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Abeona Therapeutics	$5.82M	53.76	$71.18M	$1.03	5.33

Compass Pathways currently has a consensus price target of $20.58, indicating a potential upside of 98.49%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 246.08%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Compass Pathways had 7 more articles in the media than Abeona Therapeutics. MarketBeat recorded 23 mentions for Compass Pathways and 16 mentions for Abeona Therapeutics. Compass Pathways' average media sentiment score of 0.81 beat Abeona Therapeutics' score of 0.42 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Compass Pathways' return on equity of -31.07% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Compass Pathways beats Abeona Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$312.90M	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.34%	2.81%	5.27%
P/E Ratio	5.66	18.50	20.66	25.27
Price / Sales	53.76	284.58	552.35	75.59
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	2.16	6.63	9.87	6.90
Net Income	$71.18M	$24.40M	$3.57B	$334.66M
7 Day Performance	-6.95%	4.14%	0.23%	0.12%
1 Month Performance	-0.18%	-4.80%	-2.54%	-0.18%
1 Year Performance	-10.00%	62.87%	33.54%	30.62%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	2.5745 of 5 stars	$5.49 -2.0%	$19.00 +246.1%	-10.0%	$312.90M	$5.82M	5.66	90	News Coverage Earnings Report Analyst Upgrade Insider Trade
GHRS GH Research	3.1229 of 5 stars	$21.26 -0.7%	$40.13 +88.7%	+94.8%	$1.33B	N/A	N/A	10	News Coverage Earnings Report Analyst Forecast
CRVS Corvus Pharmaceuticals	2.2387 of 5 stars	$15.81 +1.7%	$33.33 +110.8%	+241.0%	$1.31B	N/A	N/A	30	Options Volume Analyst Revision
OLMA Olema Pharmaceuticals	2.0183 of 5 stars	$14.86 -0.3%	$44.40 +198.8%	+188.5%	$1.30B	N/A	N/A	70	News Coverage Earnings Report Analyst Forecast Analyst Revision
MAZE Maze Therapeutics	2.1474 of 5 stars	$25.52 -2.0%	$66.00 +158.6%	+176.3%	$1.30B	N/A	N/A	121	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. GHRS, CRVS, OLMA, MAZE, and CMPS

How does Abeona Therapeutics compare to GH Research?

Summary

How does Abeona Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Abeona Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Abeona Therapeutics compare to Maze Therapeutics?

Summary

How does Abeona Therapeutics compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. GHRS, CRVS, OLMA, MAZE, and CMPS

How does Abeona Therapeutics compare to GH Research?

Which has more risk & volatility, GHRS or ABEO?

Do analysts recommend GHRS or ABEO?

Is GHRS or ABEO more profitable?

Does the media prefer GHRS or ABEO?

Do institutionals & insiders have more ownership in GHRS or ABEO?

Which has stronger earnings & valuation, GHRS or ABEO?

Summary

How does Abeona Therapeutics compare to Corvus Pharmaceuticals?

Which has more volatility and risk, CRVS or ABEO?

Do insiders and institutionals have more ownership in CRVS or ABEO?

Which has higher earnings and valuation, CRVS or ABEO?

Does the media favor CRVS or ABEO?

Do analysts recommend CRVS or ABEO?

Is CRVS or ABEO more profitable?

Summary

How does Abeona Therapeutics compare to Olema Pharmaceuticals?

Which has more volatility and risk, OLMA or ABEO?

Do insiders and institutionals have more ownership in OLMA or ABEO?

Which has higher earnings and valuation, OLMA or ABEO?

Does the media favor OLMA or ABEO?

Do analysts recommend OLMA or ABEO?

Is OLMA or ABEO more profitable?

Summary

How does Abeona Therapeutics compare to Maze Therapeutics?

Do institutionals and insiders have more ownership in ABEO or MAZE?

Which has better valuation and earnings, ABEO or MAZE?

Do analysts rate ABEO or MAZE?

Does the media refer more to ABEO or MAZE?

Which has more risk & volatility, ABEO or MAZE?

Is ABEO or MAZE more profitable?

Summary

How does Abeona Therapeutics compare to Compass Pathways?

Do institutionals & insiders have more ownership in CMPS or ABEO?

Which has better valuation and earnings, CMPS or ABEO?

Do analysts rate CMPS or ABEO?

Does the media favor CMPS or ABEO?

Which has more volatility & risk, CMPS or ABEO?

Is CMPS or ABEO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools